BeiGene, Ltd.
Index- P/E- EPS (ttm)-20.42 Insider Own0.10% Shs Outstand102.46M Perf Week-2.51%
Market Cap19.52B Forward P/E- EPS next Y-12.22 Insider Trans-12.75% Shs Float60.16M Perf Month11.30%
Income-2005.20M PEG- EPS next Q-5.18 Inst Own53.50% Short Float3.79% Perf Quarter48.39%
Sales1.07B P/S18.27 EPS this Y20.60% Inst Trans-1.43% Short Ratio8.10 Perf Half Y-2.52%
Book/sh57.44 P/B3.43 EPS next Y21.30% ROA-20.60% Target Price281.84 Perf Year-28.61%
Cash/sh63.08 P/C3.13 EPS next 5Y37.00% ROE-29.60% 52W Range118.18 - 426.56 Perf YTD-27.23%
Dividend- P/FCF- EPS past 5Y-31.70% ROI-20.60% 52W High-53.78% Beta0.66
Dividend %- Quick Ratio4.90 Sales past 5Y305.70% Gross Margin78.30% 52W Low66.83% ATR10.86
Employees8300 Current Ratio5.00 Sales Q/Q-49.40% Oper. Margin- RSI (14)59.98 Volatility4.91% 5.34%
OptionableYes Debt/Eq0.10 EPS Q/Q-716.50% Profit Margin- Rel Volume0.44 Prev Close193.97
ShortableYes LT Debt/Eq0.03 EarningsAug 04 BMO Payout- Avg Volume281.62K Price197.16
Recom2.10 SMA207.97% SMA5016.59% SMA200-9.10% Volume123,887 Change1.64%
Aug-09-22Resumed JP Morgan Overweight $296
Mar-17-22Downgrade SVB Leerink Outperform → Mkt Perform $300 → $177
Feb-07-22Initiated Deutsche Bank Buy
Oct-12-21Initiated Bernstein Outperform $431
Oct-06-21Upgrade CLSA Underperform → Buy
Mar-08-21Initiated China Renaissance Buy
Mar-01-21Downgrade CLSA Outperform → Underperform $330 → $321
Nov-09-20Downgrade Ladenburg Thalmann Buy → Neutral
Nov-06-20Downgrade Piper Sandler Neutral → Underweight $175 → $185
Nov-06-20Downgrade Maxim Group Buy → Hold
Jul-10-20Downgrade CLSA Buy → Outperform
Mar-13-20Upgrade Macquarie Underperform → Neutral
Feb-18-20Resumed Goldman Buy
Jan-17-20Upgrade CLSA Outperform → Buy
Jan-17-20Resumed Morgan Stanley Overweight $210
Dec-16-19Downgrade Piper Jaffray Overweight → Neutral
Dec-16-19Downgrade Guggenheim Buy → Neutral
Nov-19-19Downgrade UBS Buy → Neutral
Nov-13-19Downgrade CLSA Buy → Outperform
Nov-04-19Reiterated Maxim Group Buy $170 → $210
Aug-15-22 07:24PM  
Aug-14-22 10:09AM  
Aug-09-22 06:00AM  
Aug-08-22 09:03AM  
Aug-04-22 07:00AM  
Aug-03-22 08:54AM  
Aug-02-22 09:11AM  
Jul-27-22 12:00PM  
Jul-14-22 02:53PM  
Jul-13-22 09:00AM  
Jul-12-22 06:38PM  
Jul-06-22 07:00AM  
Jun-30-22 04:00AM  
Jun-22-22 08:10AM  
Jun-21-22 03:10PM  
Jun-20-22 08:53AM  
Jun-13-22 07:30AM  
Jun-10-22 07:00AM  
Jun-09-22 06:18AM  
Jun-08-22 10:51AM  
Jun-07-22 03:25PM  
May-26-22 05:00PM  
May-17-22 01:00AM  
May-12-22 10:00AM  
May-11-22 04:09PM  
May-09-22 03:15PM  
May-05-22 11:30AM  
May-04-22 01:48PM  
Apr-29-22 07:00AM  
Apr-28-22 07:00AM  
Apr-27-22 10:00AM  
Apr-26-22 07:00AM  
Apr-25-22 04:09PM  
Apr-21-22 07:00AM  
Apr-19-22 11:33AM  
Apr-15-22 06:00AM  
Apr-13-22 03:00AM  
Apr-12-22 10:23AM  
Apr-11-22 06:00AM  
Apr-08-22 07:00AM  
Apr-07-22 12:05PM  
Apr-06-22 05:00AM  
Apr-05-22 07:28AM  
Apr-04-22 04:11PM  
Apr-03-22 02:34PM  
Mar-28-22 06:25AM  
Mar-26-22 05:55AM  
Mar-22-22 05:03AM  
Mar-17-22 05:38AM  
Mar-16-22 02:53PM  
Mar-15-22 08:00AM  
Mar-14-22 09:54AM  
Mar-11-22 07:09AM  
Mar-10-22 07:40PM  
Mar-07-22 10:53AM  
Mar-03-22 07:00AM  
Mar-01-22 05:30AM  
Feb-25-22 07:00AM  
Feb-22-22 12:17PM  
Feb-17-22 05:00AM  
Feb-08-22 06:00AM  
Feb-01-22 07:00AM  
Jan-28-22 05:00AM  
Jan-25-22 12:17PM  
Jan-24-22 05:00AM  
Jan-20-22 05:00AM  
Jan-19-22 02:07PM  
Jan-16-22 10:30AM  
Jan-06-22 07:30AM  
Dec-28-21 09:50AM  
Dec-27-21 10:15AM  
Dec-26-21 03:38AM  
Dec-21-21 10:42AM  
Dec-20-21 09:02AM  
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wang Julia AijunChief Financial OfficerJul 01Sale158.5029546,7580Jul 05 05:29 PM
Wang LaiGlobal Head of R&DJun 27Sale177.3245881,2150Jun 28 05:32 PM
Wu XiaobinPresident, COO & GM ChinaJun 21Sale144.361,010145,8040Jun 22 05:45 PM
Wang LaiGlobal Head of R&DJun 21Sale149.01723107,7340Jun 22 05:47 PM
Wang LaiGlobal Head of R&DJun 17Sale139.4044562,034723Jun 22 05:47 PM
Wu XiaobinPresident, COO & GM ChinaJun 17Sale139.6057880,6911,010Jun 22 05:45 PM
Wang Julia AijunChief Financial OfficerJun 17Sale136.6416121,9990Jun 21 05:09 PM
Wu XiaobinPresident, COO & GM ChinaJun 06Sale141.993,410484,2020Jun 08 05:42 PM
Wang LaiGlobal Head of R&DJun 06Sale142.0066093,7180Jun 08 05:43 PM
Wang LaiGlobal Head of R&DMay 17Option Exercise3.261,233,9474,025,7371,408,498May 19 04:39 PM
Wu XiaobinPresident, COO & GM ChinaMay 05Sale164.356,7251,105,2760May 06 05:15 PM
Huang JaneCMO, HematologyDec 14Option Exercise119.961,500179,9401,500Dec 16 05:50 PM
Huang JaneCMO, HematologyDec 14Sale278.141,500417,2110Dec 16 05:50 PM
Huang JaneCMO, HematologyDec 01Sale359.861,049377,4930Dec 02 06:21 PM
Huang JaneCMO, HematologyNov 17Option Exercise119.961,500179,9401,500Nov 19 06:18 PM
Huang JaneCMO, HematologyNov 17Sale381.341,500572,0030Nov 19 06:18 PM
Wu XiaobinPresident, COO & GM ChinaNov 09Sale366.342,334855,0380Nov 10 05:14 PM
Wu XiaobinPresident, COO & GM ChinaNov 08Sale355.817,6662,727,6250Nov 10 05:14 PM
Wang XiaodongChair, Scientific Advisory BrdNov 08Sale350.044,5001,575,2020Nov 10 05:30 PM
Wang XiaodongChair, Scientific Advisory BrdNov 08Sale349.814,5001,574,1480Nov 10 05:25 PM
Huang JaneCMO, HematologyOct 19Option Exercise119.961,500179,9401,500Oct 21 05:37 PM
Huang JaneCMO, HematologyOct 19Sale372.781,500559,1630Oct 21 05:37 PM
BeiGene, Ltd.10% OwnerSep 24Buy2.852,543,8007,249,8307,348,437Sep 28 05:48 PM
Huang JaneCMO, HematologySep 20Option Exercise119.966,000719,7606,000Sep 22 06:15 PM
Huang JaneCMO, HematologySep 20Sale397.966,0002,387,7740Sep 22 06:15 PM
OYLER JOHNChief Executive OfficerSep 15Sale71.36216,36115,439,4600Sep 16 06:06 PM
OYLER JOHNChief Executive OfficerSep 14Sale93.87195,47718,348,8600Sep 16 06:06 PM
Huang JaneCMO, HematologySep 13Sale358.1412,9014,620,3900Sep 15 06:16 PM
AMGEN INC10% OwnerSep 10Buy302.06165,52949,999,93818,943,802Sep 13 07:27 PM
OYLER JOHNChief Executive OfficerSep 02Sale328.2124,4998,040,8090Sep 02 08:40 PM
Huang JaneCMO, HematologySep 02Sale327.18545178,3140Sep 02 08:39 PM
Huang JaneCMO, HematologySep 01Sale310.53542168,3070Sep 02 08:39 PM
OYLER JOHNChief Executive OfficerSep 01Sale74.56153,05911,411,6480Sep 02 08:40 PM
OYLER JOHNChief Executive OfficerAug 31Sale110.13111,08112,232,8670Sep 02 08:40 PM